Suppr超能文献

挽救性脐带血移植采用短期减低强度预处理方案治疗移植物失败。

Salvage Cord Blood Transplantation Using a Short-term Reduced-intensity Conditioning Regimen for Graft Failure.

机构信息

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Japan.

Department of Hematology, Faculty of Medicine, University of Tsukuba, Japan.

出版信息

Intern Med. 2022 Jun 1;61(11):1673-1679. doi: 10.2169/internalmedicine.7836-21. Epub 2021 Nov 20.

Abstract

Objective Graft failure (GF) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). A standardized conditioning regimen and an appropriate graft source of salvage HSCT for GF have not yet been established. Some case series have shown good hematopoietic recoveries after salvage HSCT using a short-term reduced-intensity preparative regimen consisting of fludarabine (30-90 mg/m), cyclophosphamide (2 g/m), and total-body irradiation (2 Gy). However, the dose of fludarabine has varied in these reports based on the clinical condition of the patients, resulting in very limited experiences with each dose of fludarabine. Methods We retrospectively analyzed 10 patients who developed GF after allogeneic HSCT and underwent salvage cord blood transplantation (CBT) using the above-mentioned conditioning regimen with a fixed dose (90 mg/m) of fludarabine. Results Eight patients (80.0%) achieved neutrophil engraftment within 30 days from salvage HSCT with a median of 21 (range, 17-23) days. The 1-year overall survival (OS) rate after the salvage HSCT was 50.0%, and the median OS was 281 (range, 23-1,638) days. Cumulative incidences of non-relapse mortality and relapse at 1 year were 50.0% and 10.0%, respectively. Conclusion CBT using this short-term reduced-intensity conditioning regimen may be a promising salvage therapy for GF.

摘要

目的

移植物失败(GF)是造血干细胞移植(HSCT)的一种危及生命的并发症。目前尚未建立针对 GF 的标准预处理方案和合适的挽救性 HSCT 供体。一些病例系列研究表明,采用由氟达拉滨(30-90mg/m)、环磷酰胺(2g/m)和全身照射(2Gy)组成的短期、低强度预处理方案进行挽救性 HSCT 后,造血恢复良好。然而,这些报告中氟达拉滨的剂量因患者的临床状况而异,导致对每种剂量的氟达拉滨的经验非常有限。方法:我们回顾性分析了 10 例在异基因 HSCT 后发生 GF 并接受上述预处理方案(氟达拉滨剂量固定为 90mg/m)进行挽救性脐带血移植(CBT)的患者。结果:8 例患者(80.0%)在挽救性 HSCT 后 30 天内实现了中性粒细胞植入,中位数为 21 天(范围,17-23 天)。挽救性 HSCT 后 1 年的总生存率(OS)为 50.0%,中位 OS 为 281 天(范围,23-1638 天)。1 年时非复发死亡率和复发累积发生率分别为 50.0%和 10.0%。结论:采用这种短期、低强度预处理方案的 CBT 可能是 GF 的一种有前途的挽救性治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6a6/9259308/a293829d77b4/1349-7235-61-1673-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验